Prevents malaria. ANDA 211744, held by Alembic. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 211744 (Doxycycline Hyclate), held by Alembic, was first approved by FDA on Jun 30, 2020, with 0 approved supplements and 0 published complete response letters.
Doxycycline hyclate tablets are tetracycline class drugs indicated for: · Rickettsial infections · Sexually transmitted infections · Respiratory tract infections · Specific bacterial infections · Ophthalmic infections · Anthrax, including inhalational anthrax (post-exposure) · Alternative treatment for selected infections when penicillin is contraindicated · Adjunctive therapy for acute intestinal amebiasis and severe acne · Prophylaxis of malaria To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or stro…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2020 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters